Akebia Therapeutics Details Vafseo Commercial Push, TIW Dosing Plans and Kidney Pipeline at Leerink Conference [Yahoo! Finance]
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Yahoo! Finance
showing reduced mortality/hospitalization and ~8% fewer hospitalizations (˜$3,700 saved per patient annually); Akebia is pursuing observed TIW dosing and running VOICE and VOCAL studies to support adherence and potential label changes. With TDAPA ending, Akebia expects pricing to settle “in and around the ESAs” (~$2,000–$2,500/year), likely causing a near-term revenue divot , but management sees a post-TDAPA market opportunity of about $1 billion and a potential $500M+ product if Vafseo becomes standard of care. Akebia is expanding its kidney-focused pipeline: praliciguat has entered a Phase II study in FSGS, and acquired asset AKB-097 will start an open-label basket study in IgAN, lupus nephritis and C3G in H2 with data expected to emerge in 2027. Interested in Akebia Therapeutics, Inc.? Here are five stocks we like better. Akebia Therapeutics Surges on FDA Approval for Anemia Treatment Akebia Therapeutics (NASDAQ:AKBA) executives outlined the company's near- and mid-term p
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
- How The Akebia Therapeutics (AKBA) Story Is Shifting As Vafseo Revenue Assumptions Reset [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare ConferenceGlobeNewswire
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
AKBA
Earnings
- 2/26/26 - Miss
AKBA
Sec Filings
- 3/5/26 - Form 4
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- AKBA's page on the SEC website